Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07266441 · ClinicalTrials.gov registry record · Phase 2

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 2
Development phase
157
Enrollment target
20
Study locations

NCT07266441 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 157 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07266441, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 2
Development phase
157 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG JNJ-79635322

Study Locations (20)

Other

  • Ha'Emek Medical Center - Afula
  • Samson Assuta Ashdod University Hospital - Ashdod
  • Hillel Yaffe Medical Center - Hadera
  • Hadassah Medical Center - Jerusalem
  • Rabin Medical Center - Petah Tikva

California

  • City of Hope - Duarte
  • City of Hope Orange County Lennar Foundation Cancer Center - Irvine
  • Cancer and Blood Specialty Clinic - Los Alamitos

Georgia

  • Emory University - Atlanta
  • Northside Hospital Cancer Institute - Atlanta

Iowa

  • University of Iowa - Iowa City
  • Mission Cancer Blood - Waukee

Texas

  • MD Anderson Cancer Center - Houston
  • Oncology Consultants Texas - Houston

Florida

  • Cancer Specialists of North Florida - Jacksonville

Illinois

  • Cancer Care Specialists of Central Illinois - O'Fallon

New Jersey

  • Rutgers Cancer Institute - New Brunswick

Trial Details

FieldValue
Enrollment Target 157 participants
Start Date 2026-02-08
Est. Completion 2028-12-12
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07266441

The ClinicalTrials.gov registry entry for NCT07266441 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (71% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which JNJ-79635322 is the first listed.

NCT07266441 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT07266441 about?

NCT07266441 is a clinical study titled "A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refra...

What is the current status of trial NCT07266441?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2026-02-08. Estimated completion is 2028-12-12.

What conditions does trial NCT07266441 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT07266441?

The interventions under investigation include: JNJ-79635322 (DRUG).

Who is sponsoring clinical trial NCT07266441?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07266441 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.